Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KPTI 
Karyopharm Therapeutics Inc (KPTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KPTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.38% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.17M USD | Price to earnings Ratio - | 1Y Target Price 48.93 |
Price to earnings Ratio - | 1Y Target Price 48.93 | ||
Volume (30-day avg) 164100 | Beta 0.11 | 52 Weeks Range 3.51 - 21.60 | Updated Date 04/2/2025 |
52 Weeks Range 3.51 - 21.60 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -52.62% | Operating Margin (TTM) -102.42% |
Management Effectiveness
Return on Assets (TTM) -36.88% | Return on Equity (TTM) -891.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 115604650 | Price to Sales(TTM) 0.24 |
Enterprise Value 115604650 | Price to Sales(TTM) 0.24 | ||
Enterprise Value to Revenue 0.8 | Enterprise Value to EBITDA -1.85 | Shares Outstanding 8416000 | Shares Floating 7246856 |
Shares Outstanding 8416000 | Shares Floating 7246856 | ||
Percent Insiders 6.86 | Percent Institutions 48.45 |
Analyst Ratings
Rating 4.14 | Target Price 4.5 | Buy 4 | Strong Buy 2 |
Buy 4 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Karyopharm Therapeutics Inc
Company Overview
History and Background
Karyopharm Therapeutics Inc. was founded in 2008. The company focuses on discovering, developing, and commercializing novel therapies for the treatment of cancer and other diseases. A significant milestone was the FDA approval of XPOVIO (selinexor) in 2019. The company has evolved from a research-focused entity to a commercial-stage pharmaceutical company.
Core Business Areas
- Oncology: Focuses on developing and commercializing treatments for hematologic malignancies and solid tumors.
- Global Expansion: Expanding global access to their therapies through partnerships and direct commercialization.
- Drug Discovery: Research and development of new drug candidates targeting various diseases.
Leadership and Structure
Dr. Richard Paulson is the President and CEO. The company operates with a functional structure, with dedicated teams for research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- XPOVIO (selinexor): A first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound indicated for the treatment of multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and endometrial cancer. Revenue from XPOVIO was approximately $100 million in 2023. Competitors include treatments from Amgen (AMGN), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The oncology market is rapidly growing, driven by an aging population, increased cancer incidence, and advancements in treatment options. The market is characterized by intense competition and high regulatory scrutiny.
Positioning
Karyopharm is positioned as an innovator in the SINE inhibitor space. Its competitive advantage lies in its novel mechanism of action and its focus on difficult-to-treat cancers.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars globally. Karyopharm's positioning in niche indications like relapsed/refractory multiple myeloma and DLBCL allows it to address a significant portion of this market, potentially worth billions.
Upturn SWOT Analysis
Strengths
- Novel SINE inhibitor technology
- FDA-approved product (XPOVIO)
- Experienced management team
- Strong IP protection for selinexor
Weaknesses
- Reliance on a single product (XPOVIO)
- Limited financial resources compared to larger pharmaceutical companies
- Commercial execution challenges
- Regulatory hurdles and potential for negative trial results
Opportunities
- Expanding indications for XPOVIO
- Developing new SINE inhibitors
- Strategic partnerships and collaborations
- Geographic expansion
Threats
- Competition from established cancer therapies
- Patent expiry
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AMGN
- BMY
- JNJ
Competitive Landscape
Karyopharm faces intense competition from established pharmaceutical companies. Its advantage lies in its novel SINE inhibitor technology, but it must overcome challenges related to commercial execution and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Karyopharm has experienced growth in revenue following the FDA approval of XPOVIO. Its growth is tied to the performance of its first product.
Future Projections: Analyst estimates project continued revenue growth as XPOVIO's market penetration increases and new indications are approved. Profitability is expected in the next 3 to 5 years.
Recent Initiatives: Focus on expanding indications for XPOVIO, including ongoing clinical trials in various cancer types. Strategic initiatives include partnerships to expand commercial reach.
Summary
Karyopharm is a biotechnology company with a focus on cancer therapies. They have one approved product, XPOVIO, which is driving revenue growth. The company faces challenges related to profitability and competition, but has opportunities to expand indications and form strategic partnerships. Karyopharm needs to improve commercial execution and manage its financial resources effectively to achieve sustained success.
Similar Companies
EXEL
Exelixis Inc
EXEL
Exelixis Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Karyopharm Therapeutics Inc
Exchange NASDAQ | Headquaters Newton, MA, United States | ||
IPO Launch date 2013-11-06 | President, CEO & Director Mr. Richard A. Paulson M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 279 | Website https://www.karyopharm.com |
Full time employees 279 | Website https://www.karyopharm.com | ||
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.